China Journal of Leprosy and Skin Diseases ›› 2017, Vol. 33 ›› Issue (10): 596-598.

Previous Articles     Next Articles

Recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion protein for the treatment of impetigo herpetiformis: a case report and literature review

CHU Xiaoyan, LU Guiqing, BI Zhigang.   

  1. The Affiliated BenQ Hospital of Nanjing Medical University , Nanjing 210019, China
  • Online:2017-10-15 Published:2018-12-10
  • Contact: BI Zhigang, E-mail: eltonbi@21cn.com

Abstract: A 26-year-old female presented with widespread erythema and superficial sterile pustules for 2 months and aggravated for 1 week. The patient had a psoriatic history for 13 years and she was at 28 week of pregnancy. Laboratory examination revealed hypoalbuminemia, leukocytosis and neutrophilia. Blood and pus were culture-negative for bacilli. The diagnosis of impetigo herpetiformis was made according to the clinical manifestations and laboratory parameters. The patient was treated with human immunoglobulin 20mg and ceftriaxone 1.0 g, once a day for 2 weeks with poor improvement and the recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion protein was used additionally, 25 mg, twice a week for 2 weeks. The treatment was effective and a healthy baby was delivered.

Key words: impetigo herpetiformis, recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion protein